Cel-Sci (NYSEAMERICAN:CVM – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.47) EPS for the quarter, FiscalAI reports.
Cel-Sci Stock Up 3.4%
Shares of NYSEAMERICAN:CVM opened at $1.54 on Friday. The firm has a market capitalization of $26.92 million, a P/E ratio of -0.16 and a beta of 0.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.54 and a current ratio of 0.60. The stock has a 50 day moving average price of $1.23 and a 200-day moving average price of $2.71. Cel-Sci has a 52-week low of $0.89 and a 52-week high of $13.48.
Institutional Trading of Cel-Sci
A number of hedge funds have recently made changes to their positions in CVM. Vanguard Group Inc. increased its stake in Cel-Sci by 59.7% during the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after purchasing an additional 109,352 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Cel-Sci by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock worth $417,000 after buying an additional 18,432 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after buying an additional 39,190 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Cel-Sci by 133.0% during the first quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock valued at $115,000 after buying an additional 20,484 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Cel-Sci by 9.9% during the fourth quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after buying an additional 2,300 shares during the last quarter. 12.08% of the stock is owned by institutional investors.
Cel-Sci Company Profile
CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.
The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.
Further Reading
- Five stocks we like better than Cel-Sci
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
Receive News & Ratings for Cel-Sci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cel-Sci and related companies with MarketBeat.com's FREE daily email newsletter.
